BioSpace News Archive

Satsuma Pharmaceuticals, Inc. announced the pricing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $15.00 per share, for gross proceeds of $82.5 million, before the underwriting discounts and commissions.

The 100+ site global Phase 3 clinical trial is the first-of-its-kind to leverage continuous multivariate wearable sensor data and Artificial Intelligence-based analytics

The full-day meeting will feature recognized experts sharing the latest clinical data in oncology while exploring best practices and management strategies

A New Psychiatric Services Program Has Opened in Louisville, Kentucky

BioAxone BioSciences, Inc., a biotechnology company committed to applying an innovative understanding of axon regeneration and neuronal signaling to transform the lives of patients afflicted with neurotrauma or neurovascular disorders, today announced the publication in Translational Stroke Research of data indicating that BA-1049 has promise as a therapeutic agent for the treatment of Cavernous Angioma (CA)

Greenwood Genetic Center utilizes Emedgene’s AI to slash turnaround times, improve diagnostic yield and return answers to patients faster. Emedgene’s platform automates much of the genomic analysis workflow, allowing Greenwood to reduce time-per-test by 75%.

111, Inc. (NASDAQ: YI) (“111" or the “Company”), a leading integrated online and offline healthcare platform, today announced the signing of a strategic cooperation agreement with Dong-E-E-Jiao Co., Ltd. (“DEEJ”) (SZ: 000423), a leading company principally engaged in the research, development, production and sale of traditional Chinese medicines of Ejiao and Ejiao series products in China

If nothing changes, by 2030 nearly half of all adults will be affected by obesity.

United Spinal Association will gather over 50 affiliated chapter leaders in Las Vegas, Nevada, October 3-5 for its 7th Annual Chapter Leadership Meeting to improve the quality of life and independence of its growing membership base of people with spinal cord injuries and disorders (SCI/D).

The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 32 cents per share.